Autologous hematopoietic recovery after allogeneic hematopoietic cell transplantation (allo-HCT) is rare in patients who receive myeloablative conditioning (MAC). Autologous hematopoietic recovery suggests graft rejection, leading to concerns about subsequent disease relapse. ⋯ Chromosomal abnormalities were repeatedly detected without any disease relapse for eight months. The accumulation of similar cases is required to accurately assess the incidence and clinical outcomes of autologous hematopoietic recovery after CBT with MAC.
Ayumi Gomyo, Hideki Nakasone, Hidenori Wada, Shunto Kawamura, Nozomu Yoshino, Junko Takeshita, Kazuki Yoshimura, Yukiko Misaki, Aki Tanihara, Yu Akahoshi, Machiko Kusuda, Masaharu Tamaki, Koji Kawamura, Sh... more un-Ichi Kimura, Shinichi Kako, and Yoshinobu Kanda. less
Division of Hematology, Saitama Medical Center, Jichi Medical University, Japan.
Intern. Med. 2020 Oct 1; 59 (19): 2409-2414.
AbstractAutologous hematopoietic recovery after allogeneic hematopoietic cell transplantation (allo-HCT) is rare in patients who receive myeloablative conditioning (MAC). Autologous hematopoietic recovery suggests graft rejection, leading to concerns about subsequent disease relapse. We herein report a rare case of a patient with acute leukemia who experienced autologous hematopoietic recovery after cord blood transplantation (CBT) with total body irradiation-based MAC. Chromosomal abnormalities were repeatedly detected without any disease relapse for eight months. The accumulation of similar cases is required to accurately assess the incidence and clinical outcomes of autologous hematopoietic recovery after CBT with MAC.